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Summary
Combined antiretroviral treatment (cART) has reduced
mother-to-child transmission (MTCT) of the human im-
munodeficiency virus (HIV) to virtually zero in industri-
alised countries, where strictly bottle feeding is recom-
mended for HIV-infected mothers, and to as low as 0.7%
after 12 months in low-resource settings, where breast-
feeding is strongly encouraged. Given the theoretically
very low risk of transmission by breastfeeding with cART,
and the advantages and benefits of breastfeeding, also
in industrialised countries, the strong recommendation to
HIV-infected mothers to refrain from breastfeeding in this
setting may no longer be justified.
We have evaluated risks of breastfeeding for HIV MTCT
in the light of accessible cART, the general benefits of
breastfeeding, and the women's autonomy to consent to
any intervention. As we found no evidence in the literature
of HIV MTCT via breastfeeding whilst on effective cART,
we identified a situation of clinical equipoise.
We propose how to proceed in Switzerland when HIV-
infected women consider breastfeeding. We advocate a
shared decision-making process and suggest a list of top-
ics on which to provide unbiased information for the HIV-
infected mother to enable her comprehensive understand-
ing of one or the other decision.
Although breastfeeding still should not be actively recom-
mended in Switzerland, any HIV-infected mother, regard-
less of her geographical and cultural background, who
decides to breastfeed should be supported by the best
strategy to achieve optimal medical care for both herself
and her child. This includes continuous support of cART
adherence and regular maternal HIV plasma viral load
monitoring.
Keywords: HIV, mother to child transmission, MTCT, ver-
tical transmission, breast milk, breastfeeding, autonomy,
shared decision making, equipoise, Switzerland
Introduction
Reduction of mother-to-child transmission (MTCT) of the
human immunodeficiency virus (HIV) to virtually zero due
to implementation of prevention strategies, including most
importantly combined antiretroviral treatment (cART) of
the mother leading to full suppression of the HIV plasma
viral load (pVL) is one of the greatest medical successes
in fighting the HIV epidemic [1]. As HIV MTCT occurs in
up to 26% [2] after 12 months when breastfeeding mothers
are not on cART, HIV-infected mothers in industrialised
countries are advised to refrain from breastfeeding. This
contrasts with the current recommendation to breastfeed in
low-resource settings [3], which is based on the important
multiple advantages of maternal milk compared with for-
mula in such areas (e.g., increased risk of diarrhoea and
death in infants due to use of unsafe water) [4].
Little is known about the absolute risk of HIV MTCT
via breast milk whilst mothers are on cART. Nevertheless,
low HIV MTCT figures in low-resource settings, even if
HIV-infected mothers do breastfeed (PROMISE study) [5,
6] question whether a recommendation to abstain from
breastfeeding in high-income countries is still justified.
Re-evaluation is clearly of great importance as significant
advantages of breastfeeding are known.
An essential improvement in modern clinical medical prac-
tice is consideration of the patient’s autonomy when it
comes to medical decisions. The concept of the patient’s
autonomy is based on ethical principles and has only re-
cently been appreciated, as described by Hurst [7]. For the
decision on implementation of elective caesarean section
in HIV-infected patients, it was recently proposed to con-
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sider not only the individual risks and benefits but also the
autonomy of women [8].
We have evaluated the risks and benefits of breastfeeding,
including the implication of ethical principles, for the pre-
vention of HIV MTCT in the setting of accessible cART
in Switzerland. We propose how to proceed in Switzerland
when HIV-infected women consider breastfeeding. Our
evaluation may serve to provide an overall improved coun-
selling of HIV-infected mothers, regardless of their geo-
graphical and cultural background.
Why re-evaluate breastfeeding by HIV-infect-
ed women?
The current guidelines in Europe, including the Swiss rec-
ommendation, discourage HIV-infected mothers from
breastfeeding. This is based on data from periods when
well-tolerated and efficient cART was not yet available.
In the absence of cART, 15 to 30% of vaginally delivered
children of HIV-positive mothers acquire HIV, one third
during gestation and two thirds during labour [9]. In a
randomised controlled trial in cART naïve mothers from
Kenya, breastfeeding resulted in an additional 2-year HIV
MTCT rate of 16%, and the total cumulative probability of
HIV infection in the breastfeeding arm was 37% [10].
Nowadays, improved cART results in full suppression of
HIV replication in most infected individuals. This was
convincingly evidenced by cessation of molecular HIV
evolution in a treated host [11]. The effect of cART – even
when suboptimal – has led to a reduction of overall 1-year
HIV MTCT in breastfeeding mothers to 4.2% [12]. In the
Swiss HIV Cohort Study (SHCS), 96% of appropriately
treated individuals achieve full suppression of HIV pVL
[13]. Most notably, pregnant HIV-infected women show
comparable results [14], which was confirmed in the most
recent period of 2012 to 2016 by a total of 229 pregnancies
registered in the SHCS, whereof 95.9% women had full
suppression of HIV pVL prior to delivery (data on file).
Current recommendations published in 2016 by the World
Health Organization (WHO) state that “mothers living
with HIV should breastfeed for at least 12 months and
may continue breastfeeding for up to 24 months or longer
(similar to the general population) while being fully sup-
ported for cART adherence” [3]. This pertains to “settings
where national authorities have decided that the maternal
and child health services will principally promote and sup-
port breastfeeding and antiretroviral interventions as the
strategy” [15] – that is, in low-resource settings where the
reduction of overall child morbidity and mortality is the
main driver to recommending breastfeeding by HIV-infect-
ed mothers. Many HIV-infected women in Western Europe
have emigrated from countries that apply WHO guidelines
in this way. As breastfeeding is currently not supported in
European countries, this leads to confused mothers.
This is accentuated by social and cultural pressures, which
may cause difficulties and even stigmatisation of HIV-in-
fected women who are advised not to breastfeed. More-
over, there are practical and financial reasons why women
might opt to breastfeed their infant. These factors may
cause additional pressure and personal distress. Important-
ly, unanswered questions about the arguments not to
breastfeed may, in certain circumstances, result in occa-
sional breastfeeding against medical advice [16]. Women
may decide not to disclose their decision and disengage
from care because of shame or fear of judgement [17].
Breastfeeding in these situations possibly increases the risk
of HIV MTCT, for example, when cART adherence diffi-
culties are not identified promptly and dealt with adequate-
ly. Additionally, delayed diagnosis of vertical HIV infec-
tion and delayed initiation of cART in the offspring may be
a consequence.
Finally, there is urgent need to re-evaluate the situation for
HIV-infected women with a strong desire to breastfeed in
the light of improved effectiveness of cART, based on ex-
periences with the current WHO recommendations for re-
source-limited settings and recent study results (e.g., the
PROMISE study [5, 6], which is discussed below).
Thus, re-evaluation of breastfeeding by HIV-infected
mothers is likely to allow for more appropriate support of
women in this situation, including an approach of harm
reduction counselling [18] for mothers desiring to breast-
feed.
Risk of HIV MTCT during breastfeeding
whilst on suppressive cART
Upfront, we defined a so-called “optimal scenario” with
virtually zero risk of HIV MTCT wherein a pregnant
woman is (i) adherent in taking her cART, is (ii) under reg-
ular clinical care, and (iii) has a suppressed HIV pVL of
<50 RNA copies/ml throughout pregnancy and breastfeed-
ing. We then reviewed the literature to identify cases where
HIV MTCT did occur via breastfeeding whilst mothers
complied with the “optimal scenario”. For the literature
search, we used the search term expressions filtered for
publication date from 2009/01/01, core clinical journals:
(i) “mother to child transmission” HIV and (ii) “HIV trans-
mission”, additionally filtered to infant: birth–23 months.
Moreover, we identified additional literature by a PubMed
PICO search [https://pubmedhh.nlm.nih.gov/nlmd/pico/pi-
conew.php] with population: pregnancy HIV, intervention:
prevention, with comparison and outcome blank). A case
of HIV MTCT via breastfeeding despite cART in a mother-
child pair is given when the following criteria met: (i) the
mother had at least two undetectable pVL results during
pregnancy and at delivery, (ii) the child was proven not to
have acquired HIV in utero or during the peripartum peri-
od (negative HIV-RNA in the first month of life), but (iii)
subsequently HIV-RNA detection was documented during
or after the breastfeeding period.
We were not able to identify in the literature a case of HIV
MTCT via breastfeeding in the setting of the optimal sce-
nario. A recent systematic review summarised the litera-
ture on HIV MTCT through breastfeeding by mothers on
cART [12]. In six studies, cases of postpartum transmis-
sion were identified. Nevertheless, none fulfilled above-
mentioned criteria. In a randomised trial evaluating the
difference between a nucleoside reverse transcriptase in-
hibitor (NRTI) only and a protease inhibitor (PI) plus NRTI
regimen in pregnant women, at 6 months postpartum HIV
MTCT occurred in a total of eight infants (Mma Bana
Study) [19]. Six of the eight infants had acquired HIV in
utero. Two cases suggested transmission by breastfeeding
as the most likely mode of HIV MTCT at 3 months of age.
Both mothers of the HIV-infected children started cART
with abacavir, zidovudine (AZT) and lamivudine only a
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short time before delivery (25 and 97 days, respectively);
one mother still had a detectable HIV pVL at delivery and
the other mother reportedly had adherence issues. There-
fore, these two cases of HIV MTCT via breast milk do not
fulfil the criteria for an “optimal scenario” with fully sup-
pressive cART. No HIV RNA was detected in breast milk
from either mother at 1 and 3 months after delivery, ad-
ditionally lowering the likelihood of HIV MTCT through
breastfeeding. The long-term follow-up in the same study
did not identify additional cases until week 48. This re-
flects an extremely low risk of HIV MTCT with 0.3% (1
of 275) in the group of breastfeeding HIV-infected moth-
ers who received cART consisting of ritonavir boosted
lopinavir, zidovudine and lamivudine [20].
Results from interventional studies and a Cochrane review
[20–23] have provided evidence that cART is efficacious
in prevention of HIV MTCT by breast milk and have thus
informed the current WHO recommendations [3]. HIV
MTCT increases once maternal cART is stopped at 6
months in breastfeeding HIV-infected women, which sup-
ports the current WHO recommendations of life-long ART
for all (WHO option B+) [12]. As recent data from Tan-
zania suggest, increasing implementation of this strategy
is helping to further contribute to the elimination of HIV
MTCT [24]. Similarly, the recent PROMISE Study [5, 6]
compared two postpartum prevention strategies in breast-
fed children, maternal cART versus daily single dose nevi-
rapine to the child for 18 months, in over 2400 mother-
child pairs. HIV MTCT at ages 6, 9 and 12 months in the
maternal cART arm were 0.3% (95% confidence interval
[CI] 0.1–0.8), 0.6% (95% CI 0.3–1.3) and 0.7% (95% CI
0.3–1.4), respectively, and not significantly different be-
tween the two strategies [5]. Although these results con-
firm the low risk when cART is implemented, analysis of
the HIV RNA for the whole breastfeeding period is cur-
rently not yet available to prove or disprove HIV MTCT
in the “optimal scenario”, i.e., whilst on fully suppressive
cART. So far, we only have information from the first
week postpartum, when 41% of women on cART had un-
detectable HIV pVL [5, 6]. Finally, several European coun-
tries have reported single cases of breastfeeding women,
so far without any case of HIV MTCT [25]. A very recent
study from Tanzania did not identify a case of HIV MTCT
among 214 mothers who were retained in care and had sup-
pressed pVL [26]. Unfortunately, 18% of the infants were
lost to follow-up, transferred, or died before the exclusion
of HIV infection.
Our literature review revealing no case of HIV MTCT
through breastfeeding in the “optimal scenario” does not
provide absolute absence of evidence for transmission risk
in that setting. It may therefore be helpful to (i) compare
the risk of HIV MTCT via breast milk to other potential
HIV transmission situations and (ii) balance the residual
risk versus the health benefits of breastfeeding to support a
woman’s decision for or against breastfeeding on an indi-
vidual basis. Both points are discussed below.
Comparing the risk of HIV transmission
through breastfeeding whilst on cART with
other situations
To estimate the risk of HIV MTCT through breastfeeding,
we refer to situations where any risk of HIV transmission
has been remarkably reduced since introduction of effec-
tive cART:
1. The risk of HIV transmission is associated with the
HIV pVL.
– In the case of horizontal transmission [27]
– After needle stick injury [28]
– In peripartum MTCT [29]
5. cART is able to fully suppress of HIV RNA in body
compartments and fluids including blood, rectal tissue,
genital secretions, lymph node tissue, and breast milk
[23].
6. HIV transmission is effectively reduced when cART is
implemented.
– No sexual transmission observed in case of an un-
detectable HIV pVL, even when condoms are not
used [30].
– Although no robust data are available, transmission
after needle stick injuries is considered extremely
low if the source has undetectable HIV pVL [31].
The Swiss recommendations (FOPH, 2007, bulletin
31, pages 543–555) do not recommend standard
PEP but propose expert consultation in such in-
stances.
– Virtually no HIV MTCT by vaginal birth if mother
is under suppressive cART during pregnancy [8,
32].
Hence, available data indicate a very low, unmeasurable
risk of transmission whilst on fully suppressive cART.
However, it must be emphasised that HIV MTCT through
breastfeeding is different in that prolonged potential expo-
sure is possible, with cumulative exposure to significant
quantities of milk, potentially containing HIV.
Are there possible additional risks from
breastfeeding?
Mastitis may increase the risk of HIV MTCT via breast-
feeding, and prolonged exposure to cART present in breast
milk is an important consideration as potential cART toxi-
city from in-utero and peripartum exposure is well known.
Furthermore, cell-associated HIV could theoretically con-
stitute an additional risk. The following points summarise
our reflections on these topics.
– Mastitis – even when subclinical – has been shown to
increase HIV load in breast milk in women not under
suppressive cART [33]. However, this has not been
studied for the “optimal scenario”. Moreover, data from
the ZVITAMBO trial showed that mastitis was associ-
ated with postnatal transmission only when maternal
plasma HIV load was elevated [34].
– cART toxicity is well known in exposed children not in-
fected with HIV whose in-utero or postpartum exposure
to antiretrovirals was associated with persistent de-
creases in lymphocyte, neutrophil [35] and platelet
numbers, as well as an increased risk of transient lactic
acidaemia, anaemia and mitochondrial DNA depletion
[36]. However, in a recent prospective cohort study, on-
ly zidovudine exposure during pregnancy resulted in a
higher risk of metabolic adverse events [37]. Most of
these reports analysed the use of old NRTI-compounds,
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such as zidovudine, and their use as post-exposure pro-
phylaxis for neonates and not exposure through breast-
feeding [38]. Exposure to cART by breastfeeding, in
general, seems to result in much lower exposure than
established paediatric dosing. Protease inhibitor con-
centrations in breast milk are generally lower compared
with NRTIs and non-NRTIs. A systematic review found
the maximum total exposure of the child to lamivudine
and nevirapine to be 8.4 and 12.5%, respectively, of the
established paediatric dose [39]. Obviously, there is a
lack of information especially for newer drugs and, in
consequence, research on drug levels in breast milk is
still urgently needed [38]. Based on what is known, sig-
nificant cART toxicity seems rather unlikely, but cannot
be fully excluded. As safety data are limited, antiretro-
viral drugs are not licenced for breastfeeding moth-
ers. Regular re-evaluation of this topic remains crucial
and research on this should be encouraged. The risk of
cART resistance in infants through low level exposure
is less of a concern. This risk is substantial when rel-
atively high, but imperfect, levels of antiretrovirals are
achieved and high HIV pVL is present. These are the
major predictors of antiretroviral resistance [40]. For
this reason, it is crucial to rule out HIV infection, as
generally recommended in HIV exposed children.
– Breast milk contains many inhibitors of viral replication
which may inactivate a large proportion of cell-free
virions present in breast milk; infected cells thus play a
more significant role than cell-free virus in transmission
of HIV via breastfeeding. Therefore, even during effi-
cient antiretroviral therapy, a residual, stable CD4+ T
cell-associated reservoir of HIV-1 is persistently pre-
sent in breast milk [41]. However, for horizontal trans-
mission, large studies have shown that the presence of
HIV in secretions does not represent a risk for infection
if HIV pVL is suppressed [42, 43]. For breastfeeding,
the best available data come from the PROMISE study
[5, 6] which was discussed above.
Which are the possible benefits from breast-
feeding?
Breastfeeding is generally recommended for all children
[44] and is the most natural way to provide nutrition to
an infant, besides having health benefits from fostering the
contact of mother and child. Depending on the psycholog-
ical and socio-cultural background, refraining from breast-
feeding might be associated with a negative attitude of the
mother [16]. The proven health advantages of breastfeed-
ing, irrespective of HIV status, are as follows:
– Breast milk contains several bio-active anti-inflamma-
tory and antimicrobial substances that are beneficial for
the child, such as secretory IgA, lactoferrin, lysozyme
and others [45]. Some evidence is available for a trans-
fer of HIV-specific antiviral factors (IgA, IgG, lympho-
cytes) [46].
– Development of the gut microbiota is directly influ-
enced by breastfeeding, for example, through an indi-
vidualised human milk oligosaccharide composition
[47] that may even influence survival in HIV-exposed
uninfected children [48].
– Reduced obesity [49] and acute otitis media episodes
have been described [50].
– Health outcomes in preterm and low birth weight in-
fants (e.g., growth) are improved [51].
– Hormonal changes during lactation (oxytocin/cortisone
release) are considered to have beneficial effects on
uterine involution [52].
– Incidence of postpartum depression is lower [53].
– A beneficial role with regard to the future risk to devel-
op breast cancer has been suggested [54].
– Glucose homeostasis is improved and protection
against type 2 diabetes [55], in particular after gesta-
tional diabetes, has been detected [56].
A recent review summarised both short- and long-term
health benefits for both the mother and her child [4]. Al-
though these benefits have not formally been proven in an
HIV setting, there are no obvious reasons why they should
not hold true in case of the “optimal scenario”.
In summary, comparison of breastfeeding with other situ-
ations with the risk of HIV transmission suggests a very
low risk of HIV MTCT via breast milk. Balancing the po-
tential risks and benefits of breastfeeding in the “optimal
scenario” remains difficult. Most of the risks are suspected
on theoretical grounds, and the beneficial values of breast-
feeding need to be judged individually. For this reason, the
decision should be an individualised one.
Need for shared decision making in the situa-
tion of clinical equipoise
Any medical recommendation ought to be based on bal-
ancing risks and benefits. Published evidence, if available,
provides an obvious distinction of risks and benefits. Nev-
ertheless, when the potential risks and the benefits of an in-
tervention tend towards zero, balancing risks and benefits
is extremely challenging, if not impossible. Such a clinical
situation is usually defined as clinical equipoise [57].
In a recent review, Johnson et al. argued that it might
be ethically acceptable to inform a pregnant HIV-positive
woman about the possibility of breastfeeding her child
[58]. Since the “optimal scenario” meets the premise of
equipoise, we argue that informing HIV-infected mothers
fulfilling the ‘optimal scenario’ about the possibility of
breastfeeding becomes a clinical necessity. This require-
ment is strengthened if a basic principle of clinical work
is considered, which is not to decide on behalf of the pa-
tient but to respect the patient’s autonomy [7]. As recently
suggested for the mode of delivery [8], it is vital to protect
women’s autonomy regarding their view of infant feeding.
Consequently, the decision for or against breastfeeding
must follow the process of shared decision making with
any woman wishing to breastfeed. This process requires
that the HIV-infected mother receives comprehensive and
unbiased information that empowers her to understand the
risks and benefits of each decision. The healthcare
provider’s role in this process is to supply all the required
information for the decision-making process in an unbi-
ased manner, and to understand and respect the woman’s
preference and autonomy. Ideally, after exchanging this in-
formation and discussing all potential risks and benefits,
a decision is made that can be shared by all the involved
partners. This decision process should take place before
delivery. Table 1 summarises the competing arguments.
The list can be considered as a minimum set of arguments
to be discussed with the HIV-infected mother. Over time,
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this list should be adapted or extended, whenever new in-
formation becomes available.
Proposal on how to proceed when HIV-infected
women consider breastfeeding
If an HIV-infected woman decides to breastfeed after com-
pleting the shared decision-making process, she should be
medically supported with a nonjudgmental attitude, with
the overarching goal of keeping the mother and her child
in follow-up. Criteria of the “optimal scenario” are the in-
dispensable prerequisite, as sustained full HIV pVL sup-
pression is the most important risk-minimising factor in
HIV MTCT. The treating physicians should be aware of
the fact that the “optimal scenario” might not always be a
stable condition throughout pregnancy and breastfeeding,
but might be threatened by difficulties leading to subop-
timal adherence [59, 60], such as postpartum depression
or irregular sleep due to the demands of the baby. Thus,
the mothers should be encouraged to adhere throughout
the breastfeeding period [60] and advised about practical
methods to optimise adherence. Breastfeeding may mo-
tivate women to remain in care and take their cART to
protect their child. This has the potential to reduce ma-
ternal loss to medical follow-up as has frequently been ob-
served in women who stopped cART after delivery and
did not return [17]. Adherence should be strengthened by
all locally available tools (e.g., Medication Event Moni-
toring System, mobile phone reminder). Regular follow up
of treatment during breastfeeding will detect unsuppressed
HIV pVL (>50 RNA copies/ml) soon and should result
in immediate cessation of breastfeeding and evaluation of
drug adherence. After stopping breastfeeding for any rea-
son, HIV pVL testing in the child will follow (relevant
points with specifics are summarised in table 2).
Conclusion
Breastfeeding still should not be actively recommended
in Switzerland until more robust safety data are available.
However, as we were unable to ascertain evidence of HIV
MTCT via breastfeeding whilst on effective cART, in the
“optimal scenario”, and clear reasons to support breast-
feeding do exist, we propose no longer rigidly advising
HIV-infected mothers against breastfeeding in the “optimal
scenario” with a strong wish to breastfeed their children.
The woman’s autonomy with regard to infant feeding
should be respected. When balancing risks and benefits,
we identified a situation of clinical equipoise. Thus, we ad-
vocate an open discussion with the pregnant women on her
infant feeding plans during early pregnancy. In this discus-
sion, a shared decision-making process should take place.
We suggest a list of topics on which to provide unbiased
information for the HIV-infected mother and to empower
Table 1: Guidance for a shared decision-making process to decide on breastfeeding by HIV-infected mothers fulfilling the “optimal scenario”.
1. Requirements An “optimal scenario” is when the pregnant woman is (i) adherent in taking her cART, is (ii) under regular clinical care, and (iii)
has a suppressed HIV pVL of <50 RNA copies/ml throughout pregnancy.
All the involved healthcare providers should agree on an open, non-judgmental and unbiased approach towards breastfeeding.
Understand the woman’s preference before discussing risks and benefits.
Discuss arguments for and against breastfeeding including open questions and admit limitations of medical knowledge (see list-
ings under 2 and 3 below).
Inform the woman that the whole HIV care team accepts whatever the decision is and this will not affect the quality of the HIV
management offered to her.
2. List of potential RISKS associated with
breastfeeding
HIV transmission to the child cannot be ruled out.
(i) Transmission through breastfeeding in the range of 0.3–0.9% (6–24 months of breastfeeding) has been observed in the
past when women were under effective combined antiretroviral therapy (cART) during pregnancy and the breastfeeding period.
(ii) There is no formal study evaluating the risk of MTCT by HIV-infected mothers who are under suppressive cART.
(iii) Even if we are not aware of a single case of MTCT under the “optimal scenario” we cannot exclude the possibility that
such a case did or might happen.
(iv) Even though the risk of transmission may be very low, if it occurs in a single child, the consequences of HIV transmission
are lifelong for the child
Postpartum is a vulnerable period (e.g., irregular sleep, elevated risk for mood disorders) for women with the risk of impaired ad-
herence and consequently increased pVL. In this period particularly, support of adherence to cART is important.
Longer exposure to maternal antiretroviral drugs; although breast milk concentrations are low, toxicity cannot be absolutely ex-
cluded.
Episodes of mastitis might increase the risk of transmission.
An increased risk of HIV MTCT has been observed in breastfeeding untreated HIV-infected mothers when breastfeeding was
accompanied by solid food (i.e., mixed feeding). There are currently no data to support an additional risk in the “optimal sce-
nario” but it cannot be excluded. Exclusive breastfeeding during the first 4 months is generally recommended in Switzerland.
The role of cell-associated virus in breast milk as an additional possible risk is not fully understood.
3. List of potential BENEFITS arguing for
breastfeeding
Recommendations to breastfeed during the 6 months postpartum exist in many European countries including Switzerland
Parents consider breastfeeding a simple, easy and free way of providing nutrition to the infant AND/OR psychologically essential
for infant care and development.
Breastfeeding has beneficial effects for the child (though not formally proven for children of HIV-infected mothers), such as:
(i) The human microbiome is established normally with possible beneficial health consequences; e.g. lower risk to develop al-
lergies, overweight and diabetes.
(ii) Anti-inflammatory and anti-infective components in breast milk might have beneficial effect for immune-response and im-
mune-tolerance which are important to prevent the development of allergies or infectious diseases.
Beneficial effects of breastfeeding for the mother include:
(i) Improved postpartum recovery with breastfeeding helps in the involution of the uterus and reduces postpartum depression.
(ii) A beneficial role of breastfeeding to reduce the future risk to develop breast cancer and on glucose homeostasis and pro-
tection against type 2 diabetes.
cART = combined antiretroviral therapy; HIV = human immunodeficiency virus; MTCT = mother-to-child transmission: pVL = plasma viral load
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comprehensive understanding of one or the other decision.
Any HIV-infected mother, regardless of her geographical
and cultural background, who decides to breastfeed, should
be supported by the best strategy to guarantee her and her
child’s optimal medical care, cART adherence and pVL
monitoring during this phase in order to ensure the very
best medical outcome for the mother and her child.
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